Skip to main content
Top
Published in: BMC Infectious Diseases 1/2015

Open Access 01-12-2015 | Research article

Sample size considerations using mathematical models: an example with Chlamydia trachomatis infection and its sequelae pelvic inflammatory disease

Authors: Sereina A Herzog, Nicola Low, Andrea Berghold

Published in: BMC Infectious Diseases | Issue 1/2015

Login to get access

Abstract

Background

The success of an intervention to prevent the complications of an infection is influenced by the natural history of the infection. Assumptions about the temporal relationship between infection and the development of sequelae can affect the predicted effect size of an intervention and the sample size calculation. This study investigates how a mathematical model can be used to inform sample size calculations for a randomised controlled trial (RCT) using the example of Chlamydia trachomatis infection and pelvic inflammatory disease (PID).

Methods

We used a compartmental model to imitate the structure of a published RCT. We considered three different processes for the timing of PID development, in relation to the initial C. trachomatis infection: immediate, constant throughout, or at the end of the infectious period. For each process we assumed that, of all women infected, the same fraction would develop PID in the absence of an intervention. We examined two sets of assumptions used to calculate the sample size in a published RCT that investigated the effect of chlamydia screening on PID incidence. We also investigated the influence of the natural history parameters of chlamydia on the required sample size.

Results

The assumed event rates and effect sizes used for the sample size calculation implicitly determined the temporal relationship between chlamydia infection and PID in the model. Even small changes in the assumed PID incidence and relative risk (RR) led to considerable differences in the hypothesised mechanism of PID development. The RR and the sample size needed per group also depend on the natural history parameters of chlamydia.

Conclusions

Mathematical modelling helps to understand the temporal relationship between an infection and its sequelae and can show how uncertainties about natural history parameters affect sample size calculations when planning a RCT.
Appendix
Available only for authorised users
Literature
1.
go back to reference Boily M, Mâsse B, Alsallaq R, Padian NS, Eaton JW, Vesga JF, et al. HIV treatment as prevention: considerations in the design, conduct, and analysis of cluster randomized controlled trials of combination HIV prevention. PLoS Med. 2012;9:e1001250.CrossRefPubMedPubMedCentral Boily M, Mâsse B, Alsallaq R, Padian NS, Eaton JW, Vesga JF, et al. HIV treatment as prevention: considerations in the design, conduct, and analysis of cluster randomized controlled trials of combination HIV prevention. PLoS Med. 2012;9:e1001250.CrossRefPubMedPubMedCentral
2.
go back to reference Chubb MC, Jacobsen KH. Mathematical modeling and the epidemiological research process. Eur J Epidemiol. 2010;25:13–9.CrossRefPubMed Chubb MC, Jacobsen KH. Mathematical modeling and the epidemiological research process. Eur J Epidemiol. 2010;25:13–9.CrossRefPubMed
3.
go back to reference Garnett GP, Cousens S, Hallett TB, Steketee R, Walker N. Mathematical models in the evaluation of health programmes. Lancet. 2011;378:515–25.CrossRefPubMed Garnett GP, Cousens S, Hallett TB, Steketee R, Walker N. Mathematical models in the evaluation of health programmes. Lancet. 2011;378:515–25.CrossRefPubMed
4.
5.
go back to reference Cori A, Ayles H, Beyers N, Schaap A, Floyd S, Sabapathy K, et al. HPTN 071 (PopART): a cluster-randomized trial of the population impact of an HIV combination prevention intervention including universal testing and treatment: mathematical model. PLoS One. 2014;9:e84511.CrossRefPubMedPubMedCentral Cori A, Ayles H, Beyers N, Schaap A, Floyd S, Sabapathy K, et al. HPTN 071 (PopART): a cluster-randomized trial of the population impact of an HIV combination prevention intervention including universal testing and treatment: mathematical model. PLoS One. 2014;9:e84511.CrossRefPubMedPubMedCentral
6.
go back to reference Hayes R, Ayles H, Beyers N, Sabapathy K, Floyd S, Shanaube K, et al. HPTN 071 (PopART): rationale and design of a cluster-randomised trial of the population impact of an HIV combination prevention intervention including universal testing and treatment - a study protocol for a cluster randomised trial. Trials. 2014;15:57.CrossRefPubMedPubMedCentral Hayes R, Ayles H, Beyers N, Sabapathy K, Floyd S, Shanaube K, et al. HPTN 071 (PopART): rationale and design of a cluster-randomised trial of the population impact of an HIV combination prevention intervention including universal testing and treatment - a study protocol for a cluster randomised trial. Trials. 2014;15:57.CrossRefPubMedPubMedCentral
7.
go back to reference Herzog SA, Heijne JCM, Althaus CL, Low N. Describing the progression from Chlamydia trachomatis and Neisseria gonorrhoeae to pelvic inflammatory disease: systematic review of mathematical modeling studies. Sex Transm Dis. 2012;39:628–37.CrossRefPubMed Herzog SA, Heijne JCM, Althaus CL, Low N. Describing the progression from Chlamydia trachomatis and Neisseria gonorrhoeae to pelvic inflammatory disease: systematic review of mathematical modeling studies. Sex Transm Dis. 2012;39:628–37.CrossRefPubMed
8.
go back to reference Paavonen J, Weström L, Eschenbach D. Pelvic Inflammatory Disease. In: Holmes KK, Sparling PF, Stamm W, Piot P, Wasserheit J, Corey L, Cohen M, editors. Sexually Transmitted Diseases. 4th ed. New York: McGraw-Hill Medical; 2008. p. 1017–50. Paavonen J, Weström L, Eschenbach D. Pelvic Inflammatory Disease. In: Holmes KK, Sparling PF, Stamm W, Piot P, Wasserheit J, Corey L, Cohen M, editors. Sexually Transmitted Diseases. 4th ed. New York: McGraw-Hill Medical; 2008. p. 1017–50.
9.
go back to reference World Health Organization. Global Incidence and Prevalence of Selected Curable Sexually Transmitted Infections - 2008. Geneva, Switzerland: World Health Organization; 2012. World Health Organization. Global Incidence and Prevalence of Selected Curable Sexually Transmitted Infections - 2008. Geneva, Switzerland: World Health Organization; 2012.
10.
go back to reference Stamm WE. Chlamydia Trachomatis Infections of the Adult. In: Holmes KK, Sparling PF, Stamm W, Piot P, Wasserheit J, Corey L, Cohen M, editors. Sexually Transmitted Diseases. 4th ed. New York: McGraw-Hill Medical; 2008. p. 575–93. Stamm WE. Chlamydia Trachomatis Infections of the Adult. In: Holmes KK, Sparling PF, Stamm W, Piot P, Wasserheit J, Corey L, Cohen M, editors. Sexually Transmitted Diseases. 4th ed. New York: McGraw-Hill Medical; 2008. p. 575–93.
11.
go back to reference Gottlieb SL, Martin DH, Xu F, Byrne GI, Brunham RC. Summary: the natural history and immunobiology of Chlamydia trachomatis genital infection and implications for chlamydia control. J Infect Dis. 2010;201:S190–204.CrossRefPubMed Gottlieb SL, Martin DH, Xu F, Byrne GI, Brunham RC. Summary: the natural history and immunobiology of Chlamydia trachomatis genital infection and implications for chlamydia control. J Infect Dis. 2010;201:S190–204.CrossRefPubMed
12.
go back to reference Gottlieb SL, Xu F, Brunham RC. Screening and treating Chlamydia trachomatis genital infection to prevent pelvic inflammatory disease: interpretation of findings from randomized controlled trials. Sex Transm Dis. 2013;40:97–102.PubMed Gottlieb SL, Xu F, Brunham RC. Screening and treating Chlamydia trachomatis genital infection to prevent pelvic inflammatory disease: interpretation of findings from randomized controlled trials. Sex Transm Dis. 2013;40:97–102.PubMed
13.
go back to reference Haggerty CL, Gottlieb SL, Taylor BD, Low N, Xu F, Ness RB. Risk of sequelae after Chlamydia trachomatis genital infection in women. J Infect Dis. 2010;201:S134–55.CrossRefPubMed Haggerty CL, Gottlieb SL, Taylor BD, Low N, Xu F, Ness RB. Risk of sequelae after Chlamydia trachomatis genital infection in women. J Infect Dis. 2010;201:S134–55.CrossRefPubMed
14.
go back to reference Oakeshott P, Kerry S, Atherton H, Aghaizu A, Hay S, Taylor-Robinson D, et al. Community-based trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (prevention of pelvic infection) trial. Trials. 2008;9:73.CrossRefPubMedPubMedCentral Oakeshott P, Kerry S, Atherton H, Aghaizu A, Hay S, Taylor-Robinson D, et al. Community-based trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (prevention of pelvic infection) trial. Trials. 2008;9:73.CrossRefPubMedPubMedCentral
15.
go back to reference Oakeshott P, Kerry S, Aghaizu A, Atherton H, Hay S, Taylor-Robinson D, et al. Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (prevention of pelvic infection) trial. BMJ. 2010;340:c1642.CrossRefPubMedPubMedCentral Oakeshott P, Kerry S, Aghaizu A, Atherton H, Hay S, Taylor-Robinson D, et al. Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (prevention of pelvic infection) trial. BMJ. 2010;340:c1642.CrossRefPubMedPubMedCentral
16.
go back to reference Herzog SA, Althaus CL, Heijne JCM, Oakeshott P, Kerry S, Hay P, et al. Timing of progression from Chlamydia trachomatis infection to pelvic inflammatory disease: a mathematical model. BMC Infect Dis. 2012;12:187.CrossRefPubMedPubMedCentral Herzog SA, Althaus CL, Heijne JCM, Oakeshott P, Kerry S, Hay P, et al. Timing of progression from Chlamydia trachomatis infection to pelvic inflammatory disease: a mathematical model. BMC Infect Dis. 2012;12:187.CrossRefPubMedPubMedCentral
17.
go back to reference Althaus CL, Heijne JCM, Roellin A, Low N. Transmission dynamics of Chlamydia trachomatis affect the impact of screening programmes. Epidemics. 2010;2:123–31.CrossRefPubMed Althaus CL, Heijne JCM, Roellin A, Low N. Transmission dynamics of Chlamydia trachomatis affect the impact of screening programmes. Epidemics. 2010;2:123–31.CrossRefPubMed
18.
go back to reference Molano M, Meijer CJLM, Weiderpass E, Arslan A, Posso H, Franceschi S, et al. The natural course of Chlamydia trachomatis infection in asymptomatic Colombian women: a 5-year follow-up study. J Infect Dis. 2005;191:907–16.CrossRefPubMed Molano M, Meijer CJLM, Weiderpass E, Arslan A, Posso H, Franceschi S, et al. The natural course of Chlamydia trachomatis infection in asymptomatic Colombian women: a 5-year follow-up study. J Infect Dis. 2005;191:907–16.CrossRefPubMed
19.
go back to reference Kirkwood BR, Sterne JAC. Essential Medical Statistics. 2nd ed. Malden, Mass: Blackwell Science; 2003. Kirkwood BR, Sterne JAC. Essential Medical Statistics. 2nd ed. Malden, Mass: Blackwell Science; 2003.
20.
go back to reference Scholes D, Stergachis A, Heidrich FE, Andrilla H, Holmes KK, Stamm WE. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N Engl J Med. 1996;334:1362–6.CrossRefPubMed Scholes D, Stergachis A, Heidrich FE, Andrilla H, Holmes KK, Stamm WE. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N Engl J Med. 1996;334:1362–6.CrossRefPubMed
21.
go back to reference Ness RB, Hillier SL, Kip KE, Soper DE, Stamm CA, McGregor JA, et al. Bacterial vaginosis and risk of pelvic inflammatory disease. Obstet Gynecol. 2004;104:761–9.CrossRefPubMed Ness RB, Hillier SL, Kip KE, Soper DE, Stamm CA, McGregor JA, et al. Bacterial vaginosis and risk of pelvic inflammatory disease. Obstet Gynecol. 2004;104:761–9.CrossRefPubMed
22.
go back to reference Wolfram Research I. Mathematica. Champaign, Illinois: Wolfram Research, Inc.; 2014. Wolfram Research I. Mathematica. Champaign, Illinois: Wolfram Research, Inc.; 2014.
23.
go back to reference R Core Team. R: A Language and Environment for Statistical Computing. 64Bit. Vienna, Austria: R Foundation for Statistical Computing; 2014. R Core Team. R: A Language and Environment for Statistical Computing. 64Bit. Vienna, Austria: R Foundation for Statistical Computing; 2014.
24.
go back to reference Smith KJ, Cook RL, Roberts MS. Time from sexually transmitted infection acquisition to pelvic inflammatory disease development: influence on the cost-effectiveness of different screening intervals. Value Health. 2007;10:358–66.CrossRefPubMed Smith KJ, Cook RL, Roberts MS. Time from sexually transmitted infection acquisition to pelvic inflammatory disease development: influence on the cost-effectiveness of different screening intervals. Value Health. 2007;10:358–66.CrossRefPubMed
25.
go back to reference Tuite AR, Jayaraman GC, Allen VG, Fisman DN. Estimation of the burden of disease and costs of genital Chlamydia trachomatis infection in Canada. Sex Transm Dis. 2012;39:260–7.CrossRefPubMed Tuite AR, Jayaraman GC, Allen VG, Fisman DN. Estimation of the burden of disease and costs of genital Chlamydia trachomatis infection in Canada. Sex Transm Dis. 2012;39:260–7.CrossRefPubMed
26.
go back to reference Gray RT, Beagley KW, Timms P, Wilson DP. Modeling the impact of potential vaccines on epidemics of sexually transmitted Chlamydia trachomatis infection. J Infect Dis. 2009;199:1680–8.CrossRefPubMed Gray RT, Beagley KW, Timms P, Wilson DP. Modeling the impact of potential vaccines on epidemics of sexually transmitted Chlamydia trachomatis infection. J Infect Dis. 2009;199:1680–8.CrossRefPubMed
27.
go back to reference Østergaard L, Andersen B, Olesen F, Møller JK. Efficacy of home sampling for screening of Chlamydia trachomatis: randomised study. BMJ. 1998;317:26–7.CrossRefPubMedPubMedCentral Østergaard L, Andersen B, Olesen F, Møller JK. Efficacy of home sampling for screening of Chlamydia trachomatis: randomised study. BMJ. 1998;317:26–7.CrossRefPubMedPubMedCentral
28.
go back to reference Price MJ, Ades AE, Angelis D d, Welton NJ, Macleod J, Soldan K, et al. Risk of pelvic inflammatory disease following Chlamydia trachomatis infection: analysis of prospective studies with a multistate model. Am J Epidemiol. 2013;178:484–92.CrossRefPubMedPubMedCentral Price MJ, Ades AE, Angelis D d, Welton NJ, Macleod J, Soldan K, et al. Risk of pelvic inflammatory disease following Chlamydia trachomatis infection: analysis of prospective studies with a multistate model. Am J Epidemiol. 2013;178:484–92.CrossRefPubMedPubMedCentral
29.
go back to reference Manhart LE. Has the time come to systematically test for Mycoplasma genitalium? Sex Transm Dis. 2009;36:607–8.CrossRefPubMed Manhart LE. Has the time come to systematically test for Mycoplasma genitalium? Sex Transm Dis. 2009;36:607–8.CrossRefPubMed
Metadata
Title
Sample size considerations using mathematical models: an example with Chlamydia trachomatis infection and its sequelae pelvic inflammatory disease
Authors
Sereina A Herzog
Nicola Low
Andrea Berghold
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2015
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-015-0953-5

Other articles of this Issue 1/2015

BMC Infectious Diseases 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine